Hotmail
Cholesterol combo not superior to solo drug
Vytorin no better than high dose of generic form of Zocor, study says
 | Health care videos |
 Can the public option survive the Senate? Nov. 30: Senator Sheldon Whitehouse talks about how the fate of public options depends on what happens during the Senate debate on the health reform bill. |
 | INTERACTIVE |
 | Dose of reality Do health care reform headlines leave you saying “huh?” Visit msnbc.com's guide to health reform and send us claims you'd like fact-checked. |
NEWARK, N.J. - Drug developers Merck & Co. and Schering-Plough Corp. on Monday said patients with a predisposition to high cholesterol fared no better when taking their combination cholesterol drug Vytorin than with a high dose of the generic form of Zocor.
Vytorin is a combination of Zetia and Merck's Zocor, which lost patent protection in 2006. The study measured the amount of artery-clogging plaque in three areas.
It focused on a group of 720 patients with a rare condition predisposing them to high cholesterol. The patients were given either Vytorin or a high dose of generic Zocor, known as simvastatin.
In December, a congressional committee requested more information on the study. The results were delayed, the companies maintained, because of the complexity of the data.
The patients in the two-year study had rare condition called heterozygous familial hypercholesterolemia, which the companies said affected about less than 1 percent of the population.
Earlier this month, Merck CEO Richard T. Clark said he expected Vytorin to keep a secure position in the cholesterol drug market and cited several other ongoing studies in addition to this one.
Merck and Schering-Plough are conducting three additional studies, involving more than 20,000 high-risk patients.
- Discuss Story On Newsvine
-
Rate Story:
View popularLowHigh - Instant Message
MORE FROM HEALTH CARE |
 Health care Section Front |
| Add Health care headlines to your news reader: |
Resource guide